Literature DB >> 3307672

Psychiatric complications of long-term interferon alfa therapy.

P F Renault, J H Hoofnagle, Y Park, K D Mullen, M Peters, D B Jones, V Rustgi, E A Jones.   

Abstract

Ten (17%) of 58 patients with chronic viral hepatitis treated with a four- to 12-month course of recombinant human interferon alfa developed psychiatric side effects. The psychiatric side effects fell into three categories: an organic personality syndrome characterized by irritability and short temper; an organic affective syndrome marked by extreme emotional lability, depression, and tearfulness; and a delirium marked by clouding of consciousness, agitation, paranoia, and suicidal potential. These psychiatric side effects appeared after one to three months of therapy, usually improved within three to four days of decreasing the dose of interferon alfa, and invariably resolved once therapy was stopped. The organic personality and affective syndromes tended to occur in patients who received the highest dose of interferon alfa, who had relatively mild hepatitis, and who lost weight during interferon treatment. Delirium tended to occur in patients with severe hepatitis who had previous evidence of organic brain injury or dysfunction or previous drug and alcohol abuse. Failure to recognize these side effects quickly and to treat them with supportive therapy and modification of the dose of interferon alfa could result in limitation of therapy and serious personal and interpersonal consequences.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3307672

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  80 in total

1.  Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

Authors:  B R Edlin; K H Seal; J Lorvick; A H Kral; D H Ciccarone; L D Moore; B Lo
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

Review 2.  Tolerability of treatments for viral hepatitis.

Authors:  A Gervais; N Boyer; P Marcellin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

3.  Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α.

Authors:  Mario Furlanut; Giorgio Soardo; Debora Donnini; Leonardo Sechi; Loretta Franceschi
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

Review 4.  Advances in understanding mechanisms and therapeutic targets to treat comorbid depression and cardiovascular disease.

Authors:  Brittany S Pope; Susan K Wood
Journal:  Neurosci Biobehav Rev       Date:  2020-06-26       Impact factor: 8.989

5.  Psychiatric care of the patient with hepatitis C: a review of the literature.

Authors:  Muhamad Aly Rifai; Ondria C Gleason; Douha Sabouni
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

6.  Interferon-alpha induced mania during the adjuvant treatment of malignant melanoma.

Authors:  A M Ni Mhaolain; J H Thakore
Journal:  Ir J Med Sci       Date:  2007-03-30       Impact factor: 1.568

7.  The influences of cytokines as a possible substrate for the psychological effects of immunomodulation therapy in multiple sclerosis.

Authors:  N N Spirin; D S Kasatkin
Journal:  Neurosci Behav Physiol       Date:  2009-01

Review 8.  Neurobiology of resilience in depression: immune and vascular insights from human and animal studies.

Authors:  Katarzyna A Dudek; Laurence Dion-Albert; Fernanda Neutzling Kaufmann; Ellen Tuck; Manon Lebel; Caroline Menard
Journal:  Eur J Neurosci       Date:  2019-09-13       Impact factor: 3.386

Review 9.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

Review 10.  Hepatitis C: diagnosis and treatment.

Authors:  I Scotiniotis; C A Brass; P F Malet
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.